Literature DB >> 23445111

Antiplatelet and anticoagulant agents in hereditary hemorrhagic telangiectasia.

Hannah L Devlin, Anna E Hosman, Claire L Shovlin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23445111     DOI： 10.1056/NEJMc1213554

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  20 in total

Review 1.  Bleeding and clotting in hereditary hemorrhagic telangiectasia.

Authors:  Christopher Dittus; Michael Streiff; Jack Ansell
Journal:  World J Clin Cases       Date:  2015-04-16       Impact factor: 1.337

2.  Antithrombotic therapy and intracranial bleeding in subjects with sporadic brain arteriovenous malformations: preliminary results from a retrospective study.

Authors:  Carmelo Lucio Sturiale; Fabrizio Pignotti; Marzia Giordano; Angelo Porfidia; Alessio Albanese; Igor Giarretta; Alfredo Puca; Eleonora Gaetani; Sonia D'Arrigo; Ada Truma; Alessandro Olivi; Roberto Pola
Journal:  Intern Emerg Med       Date:  2018-07-30       Impact factor: 3.397

Review 3.  Pulmonary arteriovenous malformations.

Authors:  Claire L Shovlin
Journal:  Am J Respir Crit Care Med       Date:  2014-12-01       Impact factor: 21.405

4.  Percutaneous left atrial appendage closure-An alternative strategy for anticoagulation in atrial fibrillation and hereditary hemorrhagic telangiectasia?

Authors:  Veronique M M Vorselaars; Sebastiaan Velthuis; Martin J Swaans; Johannes J Mager; Repke J Snijder; Benno J W M Rensing; Lucas V A Boersma; Martijn C Post
Journal:  Cardiovasc Diagn Ther       Date:  2015-02

5.  Dietary supplement use and nosebleeds in hereditary haemorrhagic telangiectasia - an observational study.

Authors:  Basel Chamali; Helen Finnamore; Richard Manning; Michael A Laffan; Mary Hickson; Kevin Whelan; Claire L Shovlin
Journal:  Intractable Rare Dis Res       Date:  2016-05

6.  Whole genome sequences discriminate hereditary hemorrhagic telangiectasia phenotypes by non-HHT deleterious DNA variation.

Authors:  Katie E Joyce; Ebun Onabanjo; Sheila Brownlow; Fadumo Nur; Kike Olupona; Kehinde Fakayode; Manveer Sroya; Geraldine A Thomas; Teena Ferguson; Julian Redhead; Carolyn M Millar; Nichola Cooper; D Mark Layton; Freya Boardman-Pretty; Mark J Caulfield; Claire L Shovlin
Journal:  Blood Adv       Date:  2022-07-12

7.  Hemorrhage-adjusted iron requirements, hematinics and hepcidin define hereditary hemorrhagic telangiectasia as a model of hemorrhagic iron deficiency.

Authors:  Helen Finnamore; James Le Couteur; Mary Hickson; Mark Busbridge; Kevin Whelan; Claire L Shovlin
Journal:  PLoS One       Date:  2013-10-16       Impact factor: 3.240

8.  Specific cancer rates may differ in patients with hereditary haemorrhagic telangiectasia compared to controls.

Authors:  Anna E Hosman; Hannah L Devlin; B Maneesha Silva; Claire L Shovlin
Journal:  Orphanet J Rare Dis       Date:  2013-12-20       Impact factor: 4.123

9.  Circulatory contributors to the phenotype in hereditary hemorrhagic telangiectasia.

Authors:  Claire L Shovlin
Journal:  Front Genet       Date:  2015-04-09       Impact factor: 4.599

10.  Ischaemic strokes in patients with pulmonary arteriovenous malformations and hereditary hemorrhagic telangiectasia: associations with iron deficiency and platelets.

Authors:  Claire L Shovlin; Basel Chamali; Vatshalan Santhirapala; John A Livesey; Gillian Angus; Richard Manning; Michael A Laffan; John Meek; Hannah C Tighe; James E Jackson
Journal:  PLoS One       Date:  2014-02-19       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.